147 related articles for article (PubMed ID: 6601512)
1. Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations. Preliminary report.
Bubeník J; Perlmann P; Indrová M; Símová J; Jandlová T; Neuwirt J
Cancer Immunol Immunother; 1983; 14(3):205-6. PubMed ID: 6601512
[TBL] [Abstract][Full Text] [Related]
2. Tumour inhibitory effects of TCGF/IL-2/-containing preparations.
Bubeník J; Indrová M; Perlmann P; Berzins K; Mach O; Kraml J; Toulcová A
Cancer Immunol Immunother; 1985; 19(1):57-61. PubMed ID: 3872165
[TBL] [Abstract][Full Text] [Related]
3. Local treatment with human recombinant interleukin 2 inhibits growth of MC-induced sarcomas in syngeneic mice.
Bubeník J; Kieler J; Indrová M
Folia Biol (Praha); 1986; 32(3):209-11. PubMed ID: 3488924
[TBL] [Abstract][Full Text] [Related]
4. Chemoimmunotherapy of MC-induced mouse sarcomas with human recombinant interleukin 2 and cyclophosphamide: age-dependent decline of the therapeutic efficacy.
Símová J; Bubeník J; Voitenok NN; Gren E
Folia Biol (Praha); 1989; 35(3):137-42. PubMed ID: 2789150
[TBL] [Abstract][Full Text] [Related]
5. Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer.
Rosenberg SA; Eberlein TJ; Grimm EA; Lotze MT; Mazumder A; Rosenstein M
Surgery; 1982 Aug; 92(2):328-36. PubMed ID: 6980492
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of murine sarcomas with interleukin 2. I. Local administration of human recombinant IL-2 preparations.
Bubeník J; Indrová M; Toulcová A
Folia Biol (Praha); 1986; 32(6):384-91. PubMed ID: 3492396
[TBL] [Abstract][Full Text] [Related]
7. The anti-tumour efficacy of human recombinant interleukin 2. Correlation between sensitivity of tumours to the cytolytic effect of LAK cells in vitro and their susceptibility to interleukin 2 immunotherapy in vivo.
Bubeník J; Indrová M
Cancer Immunol Immunother; 1987; 24(3):269-71. PubMed ID: 3496154
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy.
Jicha DL; Mulé JJ; Rosenberg SA
J Exp Med; 1991 Dec; 174(6):1511-5. PubMed ID: 1744582
[TBL] [Abstract][Full Text] [Related]
9. Increase in sensitivity of the microcytotoxicity assay by T cell growth factor (IL-2)-containing preparations.
Indrová M; Bubeník J
Folia Biol (Praha); 1984; 30(1):43-9. PubMed ID: 6609090
[TBL] [Abstract][Full Text] [Related]
10. Active suppression of the proliferative response to interleukin-2 in tumour-bearing mice.
Zajícová A; Holán V
Folia Biol (Praha); 1990; 36(6):301-11. PubMed ID: 2279584
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of murine sarcomas with interleukin 2. II. Activation of killer cells by human recombinant IL-2.
Indrová M; Bubeník J; Toulcová A
Folia Biol (Praha); 1986; 32(6):392-8. PubMed ID: 3492397
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumour efficacy of IL-1 and IL-2.
Bubeník J; Indrová M; Holán V
Folia Biol (Praha); 1988; 34(1):42-7. PubMed ID: 3260564
[TBL] [Abstract][Full Text] [Related]
13. Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth.
Forni G; Giovarelli M; Santoni A
J Immunol; 1985 Feb; 134(2):1305-11. PubMed ID: 3871210
[TBL] [Abstract][Full Text] [Related]
14. Specific adoptive and passive immunotherapy be parabiosis for syngeneic mouse and rat tumors.
Southam CM; Bower EB; Currie VE; Babcock VI
Ann N Y Acad Sci; 1976; 277(00):505-15. PubMed ID: 1069559
[No Abstract] [Full Text] [Related]
15. Immunotherapy of a chemically-induced sarcoma in rats: characterization of the effector T cell subset and nature of suppression.
Fernandez-Cruz E; Gilman SC; Feldman JD
J Immunol; 1982 Mar; 128(3):1112-7. PubMed ID: 6460058
[TBL] [Abstract][Full Text] [Related]
16. BCG immunotherapy of a rat sarcoma.
Baldwin RW; Pimm MV
Br J Cancer; 1973 Oct; 28(4):281-7. PubMed ID: 4759936
[TBL] [Abstract][Full Text] [Related]
17. The combined effect of radiotherapy and neuraminidase-treated tumor cells on 3-methylcholanthrene-induced fibrosarcoma.
So SK; Song CW; Rios A; Simmons RL
J Surg Oncol; 1977; 9(6):527-40. PubMed ID: 592852
[TBL] [Abstract][Full Text] [Related]
18. ADCC in aging rats with methylcholanthrene-induced sarcoma (MC-Sa).
Ziółkowska M; Nowak JJ; Ryzewska A
Arch Immunol Ther Exp (Warsz); 1987; 35(6):853-62. PubMed ID: 3508042
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of repeated cycles of local IL-2 injections in mice carrying slowly growing tumour grafts.
Símová J; Bubeník J; Indrová M; Bubeníková D; Jandlová T
Folia Biol (Praha); 1993; 39(6):315-22. PubMed ID: 7926162
[TBL] [Abstract][Full Text] [Related]
20. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
